SEP-225289 is a serotonin, norepinephrine and dopamine reuptake inhibitor (SNDRI) that we are investigating for the treatment of depression. We have completed Phase I, single-blind, randomized, placebo-controlled, safety, tolerability and pharmacokinetic clinical studies for SEP-225289 and a multiple-dose, pharmacokinetic Phase II study has begun.

Triple reuptake inhibitors that can offer balanced action across each of the three neurotransmitters have the potential to offer better outcomes in the treatment of depression than currently available antidepressants.

Depression
According to the National Institute of Mental Health, depression affects nearly 21 million adult Americans in any given one-year period.